Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Immunovant Reported Topline Results From Its Phase 3 Study Of Batoclimab In Myasthenia Gravis And Initial Results From Period 1 Of Its Phase 2B Study In Chronic Inflammatory Demyelinating Polyneuropathy

Author: Benzinga Newsdesk | March 19, 2025 06:46am

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (with 64% mean IgG reduction)
Initial CIDP results from Period 1, following standard of care washout, demonstrate a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in those patients who achieved an IgG lowering greater than 70%
In both batoclimab studies, deeper IgG reductions correlated with better clinical outcomes across a range of assessments and timepoints
INDs active for both MG and CIDP with pivotal study initiations for lead asset IMVT-1402 in these indications expected imminently

Posted In: IMVT